Practice
Featured experience
Goldman Sachs $9.5 billion sale of Boyd Thermal and related business separations
We are advising Goldman Sachs Merchant Banking Division and its portfolio company Boyd on the transactions
REV Group $9 billion merger with Terex
We are advising REV Group on the transaction
Rent the Runway growth recapitalization
We advised Rent the Runway on the transactions
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Davis Polk Advises SS&C on Its Acquisition of Citigroup’s Alternative Investor Services Business
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its acquisition of Citigroup’s Alternative…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…
Davis Polk Advises PartnerRe on Its Acquisition by EXOR
Davis Polk is advising PartnerRe Ltd. in connection with its approximately $6.9 billion acquisition by EXOR S.p.A. In…
Davis Polk Advises Solvay on Its Acquisition of Cytec
Davis Polk is advising Solvay SA in connection with its $6.4 billion acquisition of Cytec Industries Inc. Under the terms of…
Natera, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000…
Davis Polk Advises Tailwind Capital on the Sale of ReTrans
Davis Polk is advising Tailwind Capital in connection with the sale of ReTrans Inc. to The Kuehne + Nagel Group. The…
Fogo de Chão, Inc. Initial Public Offering
Davis Polk advised Fogo de Chão, Inc. (“Fogo”) on its $101.5 million initial public offering of 5,073,528 shares of its…
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American…
Davis Polk Advises Markit Ltd. on Its $685 Million Secondary Offering and Concurrent $350 Million Stock Repurchase
Davis Polk advised Markit Ltd. in connection with its SEC-registered secondary offering of 27,501,271 common shares sold by…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by…